PMID- 36212973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221011
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - Efficacy of Fangfeng Tongsheng Granule Combined with Levocetirizine in the 
      Treatment of Chronic Urticaria and Its Effect on Serum Complement, IL-4, IgE, and 
      IFN-gamma Levels in Patients.
PG  - 4012416
LID - 10.1155/2022/4012416 [doi]
LID - 4012416
AB  - OBJECTIVES: To investigate the efficacy of Fangfeng Tongsheng granule combined 
      with levocetirizine in the treatment of chronic urticaria and its effect on serum 
      complement, interleukin (IL)-4, immunoglobulin E (IgE), and interferon-gamma (IFN-gamma) 
      levels in patients. METHODS: A total of 98 patients with chronic urticaria who 
      were admitted to our hospital from July 2021 to March 2022 were selected and 
      divided into random odd-even numbers. The odd numbers were included in the 
      observation group, with a total of 49 cases, and they were treated with Fangfeng 
      Tongsheng granule combined with levocetirizine; the even numbers were included in 
      the control group, with a total of 49 cases and were treated with levocetirizine 
      alone. The two groups of patients were treated continuously for 4 weeks, and the 
      clinical efficacy of the two groups was observed. Before treatment, 2 weeks and 4 
      weeks after treatment, evaluate the clinical symptom scores of patients such as 
      itching, flushing, wheal, edema, observe the improvement of clinical symptoms of 
      patients, and the changes in Dermatology Life Quality Index (DLQI). Serum 
      complement C3, C4, T lymphocyte subsets CD(3) (+), CD(4) (+), CD(8) (+) levels 
      and CD(4) (+)/CD(8) (+) ratio, IL-4, IgE, and IFN-gamma levels and the occurrence of 
      adverse reactions in the two groups were calculated and observed. All patients 
      were followed up for 2 months after treatment to observe the recurrence of 
      patients. RESULTS: The scores of clinical symptoms such as wheal, itching, 
      flushing, edema, and attack frequency in the observation group at each time point 
      after treatment were lower than those in the control group (F times were 725.365, 
      851.521, 936.411, 3943.136, and 2226.147, all P < 0.05 (F between-group were 
      40.642, 102.124, 188.523, 259.291, and 23.92, P < 0.05); the total effective rate 
      of the observation group was 93.88% (46/49), which was significantly higher than 
      that of the control group, 73.47% (36/49) (chi (2) = 7.470, P=0.006). The DLQI 
      scores of the observation group at each time point after treatment were lower 
      than those of the control group (F time was 282.214, P < 0.05; F between-group 
      was 6.546, P < 0.05). There was no significant difference in serum C4 levels 
      between the two groups at each time point (F time was 1.225, P > 0.05; F 
      between-group was 0.408, P > 0.05); serum complement C3, CD(3) (+), and CD(4) 
      (+)/the ratio of CD(8) (+) and IFN-gamma were higher than those in the control group 
      (F time was 407.352, 107.823, 32.941, and 2354.147, P < 0.05; F between-group was 
      40.941, 24.710, 54.982, and 264.921, P < 0.05); the observation group at each 
      time after treatment the levels of IgE and IL-4 were lower than those of the 
      control group (F time were 373.124 and 395.612, P < 0.05; F between-group were 
      21.802 and 62.591, P < 0.05). The incidence of adverse reactions in the 
      observation group was 12.24% (6/49) compared with 10.20% (5/49) in the control 
      group, which had no significant difference (chi (2) = 0.102, P=0.749). Both groups 
      were followed up for 2 months after treatment. The recurrence rate in the 
      observation group was 12.24% (6/49), which was lower than that in the control 
      group, which was 32.65% (16/49) (chi (2) = 5.861, P=0.015). CONCLUSION: The 
      application of Fangfeng Tongsheng granules combined with levocetirizine in 
      patients with chronic urticaria can effectively improve the clinical symptoms of 
      patients, improve clinical efficacy, reduce the impact of the disease on life, 
      improve the immune status of patients, and reduce the risk of recurrence.
CI  - Copyright (c) 2022 Duanni Xu et al.
FAU - Xu, Duanni
AU  - Xu D
AD  - Department of Outpatient, Guangzhou Institute of Dermatology, Guangzhou, 
      Guangdong 510000, China.
FAU - Li, Zhenjie
AU  - Li Z
AD  - Department of Outpatient, Guangzhou Institute of Dermatology, Guangzhou, 
      Guangdong 510000, China.
FAU - Wang, Yinan
AU  - Wang Y
AUID- ORCID: 0000-0002-6637-5273
AD  - Department of Dermatology, Hospital of Traditional Chinese Medicine of Yantai 
      City, Yantai, Shandong 264000, China.
LA  - eng
PT  - Journal Article
DEP - 20220930
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC9546688
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/10/11 06:00
MHDA- 2022/10/11 06:01
PMCR- 2022/09/30
CRDT- 2022/10/10 04:22
PHST- 2022/07/25 00:00 [received]
PHST- 2022/09/06 00:00 [accepted]
PHST- 2022/10/10 04:22 [entrez]
PHST- 2022/10/11 06:00 [pubmed]
PHST- 2022/10/11 06:01 [medline]
PHST- 2022/09/30 00:00 [pmc-release]
AID - 10.1155/2022/4012416 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Sep 30;2022:4012416. doi: 
      10.1155/2022/4012416. eCollection 2022.